Compare Inovio Pharmaceuticals Inc (INO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ross Stores, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Ross Stores, Inc. trades at $250.66 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 1028.4× Inovio Pharmaceuticals Inc's market cap, and Ross Stores, Inc. pays a 0.71% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | ROST | |
|---|---|---|
Market Cap | $78.55M | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $255.23 |
52-Week Low | $0.66 | $144.67 |
Enterprise Value | $49.56M | $81.37B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Ross Stores (ROST) trades at $254.83, near its consensus price target of $259.00, with a slight 0.16% decline. The stock shows strong fundamentals, including a 9.74% net income margin and 38.98% ROE for 2025, with recent quarterly earnings consistently beating estimates. Technical indicators are bullish, supported by positive moving averages and recent store expansion news.
The outlook remains positive due to robust earnings growth and analyst buy ratings (63.83% consensus). Key risks include high valuation multiples (P/E of 35.17) and competitive pressures in discount retail. Upside potential exists if Q2 2026 earnings beat expectations, but macroeconomic headwinds could pressure consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
